Elvitegravir
VITEKTA
Pronunciation: el-vi-TEG-ra-veer (vye-TEK-ta)
What it isHIV integrase strand transfer inhibitor; part of a boosted single-tablet regimen.
Why this oneOnce daily in a complete tablet.
What limits itRequires cobicistat boosting, which brings CYP3A4 interactions and a lower resistance barrier than dolutegravir or bictegravir.
Elvitegravir prescription history
Animated chart of estimated U.S. prescriptions per year, HIV antiretrovirals (1987–2026). Elvitegravir enters in 2014 (estimated).
FDA-approved for
- HIV-1 infection (boosted, in fixed-dose combination) (2012)
NO BOXED WARNINGS
Principal riskCobicistat boosting brings CYP3A4 interactions
Classes and tags
Clinical profile
Legacy pregnancy categoryB
Defining liabilityBoosting-related regimen interactions and risk of antiviral resistance
Open Elvitegravir in the interactive console ↗
Self-check
- Which booster is required with elvitegravir?
Cobicistat. - How does its resistance barrier compare with dolutegravir/bictegravir?
Lower.